SCHEMBL7936583

SCHEMBL7936583

C=CCC1(CC=C)C(=O)CCc2ccccc21

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.40
ADRA2A P08913 1/20 0.40
SIGMAR1 Q99720 3/20 0.39
HTR2A P28223 2/20 0.39
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39
PGR P06401 2/20 0.38
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
NPC1 O15118 1/20 0.33
MAPK13 O15264 1/20 0.33
MAPK12 P53778 1/20 0.33
MAPK11 Q15759 1/20 0.33
MAPK14 Q16539 1/20 0.33
CES1 P23141 1/20 0.33
AKR1B1 P15121 1/20 0.33
CYP2A6 P11509 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8507270 0.83 PGR (0.38) CHRM2ADRA2ASIGMAR1HTR2APGR
SCHEMBL4000051 0.81 CHRM2 (0.53) CHRM2ADRA2ASIGMAR1HTR2AHTR2C
SCHEMBL8506797 0.76 SIGMAR1 (0.36) CHRM2SIGMAR1HTR2APGRLMNA
SCHEMBL8506801 0.76 SIGMAR1 (0.36) CHRM2SIGMAR1HTR2APGRLMNA
SCHEMBL2046093 0.75 CPT1A (0.33)
SCHEMBL8506823 0.75 SLC6A2 (0.40) CHRM2ADRA2ASIGMAR1HTR2AHTR2C
SCHEMBL8506381 0.75 SIGMAR1 (0.38) CHRM2ADRA2ASIGMAR1HTR2AHTR2C
SCHEMBL10952661 0.74 LMNA (0.49) CHRM2SIGMAR1HTR2ALMNATSHR
SCHEMBL3013289 0.73 LMNA (0.42) HTR2APGRLMNANPC1CES1
SCHEMBL7935803 0.72 ALDH1A1 (0.46) CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6331636-B1 TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, DIABETES, HYPERTENSION, IMPOTENCY, APPETITE CONTROL THE UPJOHN COMPANY 2001-12-18 US disclosed
EP-0482084-B1 (1,2N) AND (3,2N)-CARBOCYCLIC-2-AMINO TETRALIN DERIVATIVES UPJOHN CO (US) 1997-05-07 EP disclosed
US-5545755-A USEFUL TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS, HYPERTENSION, DIABETES, SEXUAL IMPOTENCY AND TO CONTROL APPETITE THE UPJOHN COMPANY (US) 1996-08-13 US disclosed
US-5491236-A NERVOUS SYTEM DISORDERS THE UPJOHN COMPANY (US) 1996-02-13 US disclosed
EP-0552246-A1 THERAPEUTICALLY USEFUL 2-AMINOTETRALIN DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 1993-07-28 EP disclosed
WO-1992006967-A1 THERAPEUTICALLY USEFUL 2-AMINOTETRALIN DERIVATIVES THE UPJOHN COMPANY (US) 1992-04-30 WO disclosed
EP-0482084-A1 (1,2N) AND (3,2N)-CARBOCYCLIC-2-AMINO TETRALIN DERIVATIVES. UPJOHN CO (US) 1992-04-29 EP disclosed
EP-0476016-A1 THERAPEUTICALLY USEFUL 2-AMINOTETRALIN DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 1992-03-25 EP disclosed
WO-1991000856-A2 (1,2N) AND (3,2N)-CARBOCYCLIC-2-AMINO TETRALIN DERIVATIVES THE UPJOHN COMPANY (US) 1991-01-24 WO disclosed
WO-1990015047-A1 THERAPEUTICALLY USEFUL 2-AMINOTETRALIN DERIVATIVES THE UPJOHN COMPANY (US) 1990-12-13 WO disclosed